Literature DB >> 24923260

Retrospective cohort study evaluating the impact of intraperitoneal morcellation on outcomes of localized uterine leiomyosarcoma.

Suzanne George1, Constance Barysauskas, César Serrano, Titilope Oduyebo, Jose A Rauh-Hain, Marcela G Del Carmen, George D Demetri, Michael G Muto.   

Abstract

BACKGROUND: Uterine leiomyosarcoma (ULMS) is identified in 0.1% to 0.2% of hysterectomy specimens of presumed leiomyoma. To date, there is no preoperative technique that reliably differentiates ULMS from uterine leiomyoma. Increasing use of minimally invasive approaches for the management of leiomyomas may result in inadvertently morcellated ULMS with resultant intraperitoneal dissemination of tumor. The objective of this study was to assess the impact of intraperitoneal morcellation on the outcomes of patients with ULMS.
METHODS: In this retrospective cohort study, all patients with ULMS who attended the authors' institutions from 2007 to 2012 were reviewed. Demographics and outcomes were compared between those who underwent morcellation or total abdominal hysterectomy (TAH) as their first surgery for uterus-limited ULMS.
RESULTS: In total, 58 patients were identified, including 39 who underwent TAH and 19 who underwent intraperitoneal morcellation. Intraperitoneal morcellation was associated with a significantly increased risk of abdominal/pelvic recurrences (P = .001) and with significantly shorter median recurrence-free survival (10.8 months vs 39.6 months; P = .002). A multivariate adjusted model demonstrated a > 3 times increased risk of recurrence associated with morcellation (hazard ratio, 3.18; 95% confidence interval, 1.5-6.8; P = .003).
CONCLUSIONS: Intraperitoneal morcellation of presumed leiomyoma worsens the outcomes of women with ULMS. Because there are no reliable preoperative techniques to distinguish ULMS from benign leiomyoma, all efforts to minimize intraperitoneal uterine morcellation should be considered. [See editorial on pages 000-000, this issue.]
© 2014 American Cancer Society.

Entities:  

Keywords:  hysterectomy; morcellation; outcomes; uterine leiomyosarcoma; uterine sarcoma

Mesh:

Year:  2014        PMID: 24923260     DOI: 10.1002/cncr.28844

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  37 in total

1.  Cost-Effectiveness of Laparoscopic Hysterectomy With Morcellation Compared With Abdominal Hysterectomy for Presumed Myomas.

Authors:  Sarah E Rutstein; Matthew T Siedhoff; Elizabeth J Geller; Kemi M Doll; Jennifer M Wu; Daniel L Clarke-Pearson; Stephanie B Wheeler
Journal:  J Minim Invasive Gynecol       Date:  2015-10-22       Impact factor: 4.137

Review 2.  A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature.

Authors:  Fong W Liu; Valerie B Galvan-Turner; Krista S Pfaendler; Teresa C Longoria; Robert E Bristow
Journal:  Am J Obstet Gynecol       Date:  2015-01-09       Impact factor: 8.661

Review 3.  Soft Tissue and Uterine Leiomyosarcoma.

Authors:  Suzanne George; César Serrano; Martee L Hensley; Isabelle Ray-Coquard
Journal:  J Clin Oncol       Date:  2017-12-08       Impact factor: 44.544

4.  Disseminated Peritoneal Leiomyomatosis Status Post Laparoscopic Hysterectomy with Morcellation.

Authors:  Neil Anand; Marci Handler; Ahsan Khan; Allison Wagreich; Sean Calhoun
Journal:  J Radiol Case Rep       Date:  2016-12-31

5.  Characterization and Preoperative Risk Analysis of Leiomyosarcomas at a High-Volume Tertiary Care Center.

Authors:  Ann Peters; Amanda M Sadecky; Daniel G Winger; Richard S Guido; Ted T M Lee; Suketu M Mansuria; Nicole M Donnellan
Journal:  Int J Gynecol Cancer       Date:  2017-07       Impact factor: 3.437

6.  Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma.

Authors:  Andrew S Brohl; Li Li; Vaagn Andikyan; Sarah G Običan; Angela Cioffi; Ke Hao; Joel T Dudley; Charles Ascher-Walsh; Andrew Kasarskis; Robert G Maki
Journal:  Oncologist       Date:  2015-03-12

7.  Incidence of sarcoma in patients undergoing hysterectomy for benign indications: a population-based study.

Authors:  Francesco Multinu; Jvan Casarin; Lucia Tortorella; Yajue Huang; Amy Weaver; Stefano Angioni; Gian Benedetto Melis; Andrea Mariani; Elizabeth A Stewart; Shannon K Laughlin-Tommaso
Journal:  Am J Obstet Gynecol       Date:  2018-11-14       Impact factor: 8.661

8.  Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease.

Authors:  Jason D Wright; Rosa R Cui; Anqi Wang; Ling Chen; Ana I Tergas; William M Burke; Cande V Ananth; June Y Hou; Alfred I Neugut; Sarah M Temkin; Y Claire Wang; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2015-10-08       Impact factor: 13.506

Review 9.  Options for Adjuvant Therapy for Uterine Leiomyosarcoma.

Authors:  Claire F Friedman; Martee L Hensley
Journal:  Curr Treat Options Oncol       Date:  2018-02-08

10.  Uterine leiomyomas: correlation between histologic composition and stiffness via magnetic resonance elastography - a Pilot Study.

Authors:  Marzanna Obrzut; Bogdan Obrzut; Marcin Zmuda; Jakub Baran; Marian Cholewa; Richard Ehman; Dorota Darmochwal-Kolarz
Journal:  Ginekol Pol       Date:  2020-06-16       Impact factor: 1.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.